Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
Prostate Cancer
DEVICE: Focal Therapy for Prostate Cancer
Overall Survival, Living at 20 years after treatment, 20 years|Metastasis-Free Survival, Metastasis Free at 20 years after treatment, 20 years|Progression-Free Survival, Progression-Free (Local or Systemic) at 20 years after treatment, 20 years|Short-term Clinically Significant Prostate Cancer Recurrence, 12-18 month infield and outfield recurrence rate, 18 months|Intermediate-term Clinically Significant Prostate Cancer Recurrence, 5 year infield and outfield recurrence rate, 5 years|Sexual Function, Change in Expanded Prostate Index Composite (EPIC) Sexual Summary Score (0-100, with 100 being the maximum) post-Focal Therapy (FT) compared to baseline at 1,3, 6, 12 months, 12 months|Urinary Function, Change in Expanded Prostate Index Composite (EPIC) Urinary Summary Score (0-100, with 100 being the maximum) post-FT compared to baseline at 1,3, 6, 12 months, 12 months|Bowel Function, Change in Expanded Prostate Index Composite (EPIC) Bowel Summary Score (0-100, with 100 being the maximum) post-FT compared to baseline at 1,3, 6, 12 months, 12 months|Radical Intervention-free Survival, Free of Radical Prostatectomy or Radiation at 5 years, 5 years|Treatment Failure-free Survival, Free of Radical Prostatectomy, Radiation, Whole-gland Ablation, Hormonal Therapy to Transition to Watchful Waiting at 5 years, 5 years
Intervention-Free Survival, Intervention (Focal or Whole Gland/ Radical)-free at 20 years, 20 years|Radical Intervention-Free Survival, Radical Intervention (Radical Prostatectomy or Radiation)-Free at 20 years, 20 years|Failure-Free Survival, Failure (Whole Gland/ Radical intervention, use of Hormonal Therapy or transition to Watchful Waiting)-free at 10 years, 10 years|Failure-Free Survival, Failure (Whole Gland/ Radical intervention, use of Hormonal Therapy or transition to Watchful Waiting)-free at 20 years, 20 years
Inter-modality Comparison of short-term Oncological Outcomes, Comparison of 12-month infield and outfield recurrence rates between different focal therapy modalities, 12 months|Inter-modality Comparison of Conversion to Radical Treatment Rates, Comparison of 10 year conversion to radical treatment (Radical Prostatecomy or Radiation) between different modalities, 10 years|Inter-modality Comparison of Treatment Failure Rates, Comparison of 10 year failure (Radical Prostatectomy or Radiation or Hormonal Therapy or transition to Watchful Waiting) between different modalities, 10 years|Inter-modality Comparison of Metastasis Rates, Comparison of 10 year metastasis-rate between different modalities, 10 years|Inter-modality Comparison of Sexual Function Outcomes, Comparing mean change in Expanded Prostate Index Composite (EPIC) Sexual Summary Score (0-100, with 100 being the best function) post-FT compared to baseline at 1,3, 6, 12 months between different modalities., 12 months|Inter-modality Comparison of Urinary Function Outcomes, Comparing mean change in Expanded Prostate Index Composite (EPIC) Urinary Summary Score (0-100, with 100 being the best function) post-FT compared to baseline at 1,3, 6, 12 months between different modalities., 12 months|Inter-modality Comparison of Bowel Function Outcomes, Comparing mean change in Expanded Prostate Index Composite (EPIC) Bowel Summary Score (0-100, with 100 being the best function) post-FT compared to baseline at 1,3, 6, 12 months between different modalities., 12 months
Patients undergoing Focal Cryotherapy, Focal HIFU, Focal IRE, Focal Laser ablation, or other partial gland ablation modalities for prostate cancer will be recruited.